You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.
The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.
Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.
The firm will use the proceeds for working capital, but said it may also acquire or invest in complementary technologies or businesses.
The company hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
The company will offer 4 million shares of common stock at a price of $12.50 per share, with an option for underwriters to purchase up to an additional 600,000 shares.
NanoString Technologies hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
The firm said it will offer 4.5 million shares of its common stock at $20 per share. It expects to close its follow-on public offering on July 16.
Net proceeds from the exercise of subscription rights and warrants are anticipated to be $22.6 million, excluding any proceeds from the exercise of warrants.
The molecular diagnostics company previously raised $180 million in its 2015 initial public offering.